CERE-120: AAV2-NTN
CERE-120-01
Phase 1 gene_therapy completed
Quick answer
CERE-120: AAV2-NTN for Parkinson's Disease is a Phase 1 program (gene_therapy) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SANGAMO THERAPEUTICS, INC
- Indication
- Parkinson's Disease
- Phase
- Phase 1
- Modality
- gene_therapy
- Status
- completed